WO2004076658A1 - モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬 - Google Patents
モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬 Download PDFInfo
- Publication number
- WO2004076658A1 WO2004076658A1 PCT/JP2004/002402 JP2004002402W WO2004076658A1 WO 2004076658 A1 WO2004076658 A1 WO 2004076658A1 JP 2004002402 W JP2004002402 W JP 2004002402W WO 2004076658 A1 WO2004076658 A1 WO 2004076658A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- variable region
- cancer
- antibody
- amino acid
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 title claims description 69
- 239000000203 mixture Substances 0.000 title description 13
- 239000003153 chemical reaction reagent Substances 0.000 title description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 143
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 118
- 201000011510 cancer Diseases 0.000 claims abstract description 102
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 59
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 15
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 14
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 14
- 239000002502 liposome Substances 0.000 claims abstract description 10
- 239000003053 toxin Substances 0.000 claims abstract description 7
- 231100000765 toxin Toxicity 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 52
- 241000287828 Gallus gallus Species 0.000 claims description 37
- 230000004660 morphological change Effects 0.000 claims description 35
- 239000002773 nucleotide Substances 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 239000000835 fiber Substances 0.000 claims description 15
- 230000009257 reactivity Effects 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 210000003127 knee Anatomy 0.000 claims description 9
- 210000005048 vimentin Anatomy 0.000 claims description 9
- 102000013127 Vimentin Human genes 0.000 claims description 8
- 108010065472 Vimentin Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 210000004292 cytoskeleton Anatomy 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims 1
- 210000001268 chyle Anatomy 0.000 claims 1
- 230000006740 morphological transformation Effects 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 abstract description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 4
- 201000000050 myeloid neoplasm Diseases 0.000 abstract description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 43
- 238000000034 method Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 26
- 239000012634 fragment Substances 0.000 description 22
- 230000027455 binding Effects 0.000 description 21
- 239000000499 gel Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 239000012528 membrane Substances 0.000 description 18
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 14
- 239000002033 PVDF binder Substances 0.000 description 14
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 14
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 13
- 238000001962 electrophoresis Methods 0.000 description 13
- 201000005202 lung cancer Diseases 0.000 description 13
- 208000020816 lung neoplasm Diseases 0.000 description 13
- 101001023553 Homo sapiens NADH dehydrogenase [ubiquinone] 1 subunit C2 Proteins 0.000 description 12
- 102100035386 NADH dehydrogenase [ubiquinone] 1 subunit C2 Human genes 0.000 description 12
- 239000012228 culture supernatant Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 210000003556 vascular endothelial cell Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 229920000936 Agarose Polymers 0.000 description 8
- 241000283707 Capra Species 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 5
- 229940009456 adriamycin Drugs 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000012830 cancer therapeutic Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 239000012083 RIPA buffer Substances 0.000 description 3
- 208000000277 Splenic Neoplasms Diseases 0.000 description 3
- 229930185229 antidesmin Natural products 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 201000002471 spleen cancer Diseases 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- CCPHAMSKHBDMDS-UHFFFAOYSA-N Chetoseminudin B Natural products C=1NC2=CC=CC=C2C=1CC1(SC)NC(=O)C(CO)(SC)N(C)C1=O CCPHAMSKHBDMDS-UHFFFAOYSA-N 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000609499 Palicourea Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 210000005045 desmin Anatomy 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- -1 methotrexet Chemical compound 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 238000006677 Appel reaction Methods 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 101100379067 Caenorhabditis elegans anc-1 gene Proteins 0.000 description 1
- 101100499346 Caenorhabditis elegans dld-1 gene Proteins 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 1
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 241000425481 Ocys Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229960005552 PAC-1 Drugs 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000004662 dithiols Chemical group 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000005520 electrodynamics Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 102000034272 protein filaments Human genes 0.000 description 1
- 108091005974 protein filaments Proteins 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 235000012773 waffles Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Definitions
- the present invention relates to a novel monoclonal antibody which can be used for the treatment and diagnosis of cancer, a DNA encoding the antibody, a hybridoma producing the antibody, a pharmaceutical thread containing the antibody, and a diagnosis.
- a novel monoclonal antibody which can be used for the treatment and diagnosis of cancer, a DNA encoding the antibody, a hybridoma producing the antibody, a pharmaceutical thread containing the antibody, and a diagnosis.
- Vimentin is a filament protein of the cytoskeleton of mesenchymal cells or non-epithelial cells, and its genetic expression is known to increase by cell stimulation (Mol Cell Biol. 1987, vol. 7, No. 11, p3908-15). In addition, expression is not observed in normal epithelial cells, whereas its expression tendency is high in the cytoplasm of some poorly differentiated tumor cells such as lung gland, stomach cancer, endometrial cancer or fetal cancer. (Mol Cell Biol. 1987, vol. 7, No. 11, p3908-15). However, it was not known that Vimentin itself functions as an antigen protein. ''
- An object of the present invention is to provide a monoclonal antibody which is useful for diagnosing and treating cancers, especially non-small cancers, S-derived cancers, and gastric cancers, and has few side effects.
- the present inventors have conducted intensive studies to provide a monoclonal antibody for use in targeting therapy for cancer tissues, and as a result, have specifically identified cancer cells such as HLC-1, PANC-1 and ⁇ 45.
- the present inventors have produced a hybridoma that produces a novel human monoclonal antibody that recognizes it, and have found that a therapeutic agent for cancer useful for targeting therapy can be obtained by using this antibody.
- the present invention has been completed.
- the present invention is as follows.
- Variable member region or contains the amino acid sequence of SEQ ID NO: 86, 88 and 90, and vehicle variable region i or contains the amino acid sequence of Torii sequence number 92, 94 and 96 Monoclonal antibodies that make this difficult.
- the heavy chain variable region comprises the amino acid sequence of rooster No. 115, and it is difficult for the car 31 negative variable region to comprise the amino acid sequence of SEQ ID NO: 117.
- the region coding for the variable region of the heavy chain contains the base sequence of the rooster H ⁇ lJ Nos. 85, 87 and 89, and the region coding for the variable region of the light chain is SEQ ID NOs: 91, 93 and 95.
- the region encoding the heavy chain variable region comprises the nucleotide sequence of SEQ ID NO: 81, and the region encoding the light chain variable region comprises the nucleotide sequence of SEQ ID NO: 83, (11) Or the DNA of (12).
- the region encoding the heavy chain variable region includes the nucleotide sequence of SEQ ID NO: 114, and the region encoding the light chain variable region includes the nucleotide sequence of SEQ ID NO: 116.
- a pharmaceutical composition comprising the monoclonal antibody according to any one of (1) to (10).
- cancer therapeutic agent is a cancer therapeutic agent for one or more cancers selected from the group consisting of non-small cell lung cancer, spleen cancer, and gastric cancer.
- the morphological change is a morphological change to one or more morphologies selected from the group consisting of an axon-like morphology, an occult blast-like morphology, and a morphology having protrusions of neuronal differences.
- the polypeptide according to any one of (23) to (25).
- Figure 1 is a photograph (photograph) showing the morphological change of each cell when HoAKs-1 antibody was allowed to act on cultured females.
- FIG. 2 is a graph showing the effect of the HoAKs-1 antibody on the stimulation of HLC-1, MKN45 and HUV ECs.
- FIG. 3 is a graph showing the effect of the HoAKs-1 antibody on the control of spleen cancer cells PANC-1.
- FIG. 4 is a diagram (photograph) showing the reactivity of the HoAKs-1 antibody to various tissue sections.
- FIG. 5 is a diagram (photograph) showing the results of the analysis of the antigen protein to which the HoAKs-1 antibody reacts.
- FIG. 6 is a diagram (photograph) showing the morphological change of each cell when the Ho AKs-1 antibody is allowed to act on the culture medium for a certain period of time, and then the antibody is removed from the culture medium.
- FIG. 7 is a diagram (photograph) showing the binding activity of the HoAKs-1 antibody to each live cancer cell surface.
- FIG. 8 is a diagram (photograph) 'showing the binding activity of the anti-55 kDa mouse monoclonal antibody to the surface of each live cancer cell.
- FIG. 9 is a diagram (photograph) showing the binding activity of the r-HoA. Antibody to each live cancer cell surface.
- the monoclonal antibody of the present invention comprises an antigenic protein of about 55 kDa (human amino acid sequence of SEQ ID NO: 107) derived from human ⁇ cancer thin moon cake PAN C-1 (ATCC No. CRL 1469) shown in FIG. (Specifically, a protein).
- it is a monoclonal antibody that does not cause morphological changes in normal cells and causes morphological changes in cancer cells.
- a specific protein of about 55 kDa protein containing the amino acid sequence of SEQ ID NO: 107) derived from human pancreatic carcinoma ePANC-1 shown in Fig. 5 is specific. It is a monoclonal antibody that recognizes morphologically, does not cause morphological changes in normal cells, and causes morphological changes in cancer cells.
- Vimentin can be exemplified as the above-mentioned about 55 kDa viewing protein.
- morphological changes include, for example, the axon-shaped morphology, the ⁇ ⁇ fine morphology, and the morphology having a shin-fiber as Wei as shown in Fig. 1 (B and!).
- Form change dani
- the monoclonal antibody of the present invention include a heavy chain variable region containing amino acid sequences of Nos. 86, 88 and 90, and a carbohydrate variable region containing amino acid sequences of SEQ ID Nos. 92, 94 and 96. Things.
- the tenth amino acid may be Cys or Tyr. That is, there are two types of heavy chain variable regions, one with 1 OCys and one with 10 Tyr.
- the clear antibody may have one or several amino acid substitutions or deletions in one or more of the above six types of sequences.
- the above six types of arrangements are the regions called “hypervariable regions” in the variable regions of translatory and car fibers;
- Antibodies consist of ⁇ and ⁇ , and each chain consists of a constant region and a variable region.
- the variable region further has a hypervariable region, and this region has the specificity of immunoglobulin as an antibody and the binding property between the iJ3 ⁇ 4g3 ⁇ 43 ⁇ 4 group and the antibody. Therefore, the antibody of the present invention contains the above sequences in the hypervariable region, but the region other than the hypervariable region may be derived from another antibody.
- other antibodies include antibodies derived from organisms other than humans, but human-derived antibodies are preferable from the viewpoint of side effects iffi.
- Particularly preferred monoclonal antibodies in the present invention include: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 82; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 84; The amino acid sequence of SEQ ID NO: 1
- Antibodies comprising the 17 amino acid sequences.
- the combination of the 14th and 51st amino acids may be either (Cys, Tyr) or (Tyr, Cys). That is, there are two types of heavy chain variable region sequences, 14Cys and 51 Tyr and 14Tyr and 51 Cys.
- the 13th amino acid may be Val or I1e. In other words, there are two types of vehicle variable region arrays, 13 Va 1 and 13 I 1 e.
- the monoclonal antibody is a fragment of a monoclonal anti-monoclonal antibody, an F (ab,) dimerized anti-F (ab,) ⁇ ⁇ anti-short chain: ⁇ enhancer (scFv), a diabody (Diabodies). ) And minibodies.
- the amino acid sequence of the SI member and the constant region of the fiber can be obtained from Nucleic Acids Research vol. 14, pl779, 1986, The Journal of Biologica 1 Chemistry vol. 257, pl516, 1982 and Cell vol. .22, pl97 5 1980.
- Examples of the antibody of the present invention containing a constant region MS and a variable region include an antibody having the amino acid sequence of SEQ ID NO: 130 (heavy chain) or the rooster example number 132 (member of car II).
- the monoclonal antibody of the present invention can be obtained, for example, by culturing a hybridoma producing the antibody using a culture medium containing RPMI 1640 containing fetal bovine serum, or using the nucleotide sequence of SEQ ID NO: 81 or 83.
- a host such as a CHO cell (Chinese high-speed Yuichi ovary cell) or a bacterium by incorporating it into the ⁇ ii bek yuichi (pc DNA 3.1 (invitrogen) etc.) that enables the expression of the gene.
- Antibodies can be produced by expression and purified from these cultures using a Protein A column or the like.
- the monoclonal antibody of the present invention also comprises a protein of about 55 kDa derived from human knee cancer cell line PAN C-1 containing the amino acid sequence of SEQ ID NO: 107, preferably vimentin (GenBauk Accession No. M14144).
- a hybridoma is prepared from an animal immunized with the above, and the hybridoma is cultured, and a monoclonal antibody having a binding activity to a live cancer cell surface is selected from the obtained monoclonal antibodies.
- Examples of such a monoclonal antibody include a monoclonal antibody produced from the hybridoma 2F6-1 strain and the 3F9-1 strain shown in the Wei example described below.
- the DNA of the present invention is a DNA encoding the monoclonal antibody of the present invention.
- the region encoding the variable region of the heavy chain has the amino acid sequence of rooster H ⁇ number 86, 88 and 90.
- a region encoding a carcass variable region includes a sequence encoding the amino acid sequence of SEQ ID NO: 92, 94, or 96, respectively.
- the region encoding the variable region of the employee contains bases ⁇ J of SEQ ID NOS: 85, 87 and 89, respectively
- the region encoding the variable region of the human is SEQ ID NOS: 91, 93 and And DNAs containing the 95 and 95 base sequences, respectively.
- the 29th base may be a or g.
- the 18th base may be c or t. That is, there are two types of sequences coding for the light chain variable region: 18c and 18t. Since the hypervariable regions encoded by the DNAs of these sequences are regions that determine the specificity of the antibody, roosters encoding other regions may be roosters derived from other antibodies.
- other antibodies also include antibodies derived from organisms other than humans, but human antibodies are preferred from the viewpoint of reducing side effects.
- V Particularly preferred DN ⁇ ⁇ ⁇ ⁇ in the present invention is that the region coding for the variable member of the dust contains the sequence coding for the amino acid sequence of SEQ ID NO: 82, and the region coding for the vehicle negative variable region.
- the region encoding the amino acid sequence of SEQ ID NO: 84, or the region encoding the variable region of the heavy chain includes the sequence encoding the amino acid sequence of SEQ ID NO: 115, and the light chain
- the region encoding the variable region is DNA containing the sequence encoding the amino acid sequence of No. 117.
- particularly preferred DNAs are those in which the sequence encoding the heavy chain variable region comprises the nucleotide sequence of SEQ ID NO: 81 and the region encoding the variable region comprises the nucleotide sequence of SEQ ID NO: 83.
- the sequence encoding the NA or heavy chain variable region contains the nucleotide sequence of SEQ ID NO: 114, and the region encoding the variable region of the vehicle is DNA containing the nucleotide sequence of SEQ ID NO: 116.
- the combination of the 41st and 152nd bases may be (a, g) or (g, a).
- sequences encoding heavy chain variable regions 41a and 152g, and 41g and 152a.
- sequence of SEQ ID NO: 83 or 116 No. 37
- the combination of the bases at positions 183, and 258 may be any of (a, a, t), (a, a, c) and (g, g, t). That is, there are three types of rooster U that encodes the member variable region: 37a, 183a, 258t, 37a, 183a, 258c, and 37g, 183g, 258t. No.
- the DNA of the present invention is a monoclonal antibody that specifically recognizes a protein of about 55 kDa derived from human arm cancer-specific PANC-1 (a protein containing the amino acid of SB ⁇ J No. 107). That hybridizes under stringent conditions to the DNA containing the nucleotide sequence of SEQ ID NO: 81 and the salt of SEQ ID NO: 83, or the nucleotide sequence of SEQ ID NO: 114 and the nucleotide sequence of SEQ ID NO: 116 It may be.
- the stringent conditions include, for example, 60 ° C, lxSSC, 0.1% SDS, preferably 0.1 XSSC, 0.1% SDS, which are the washing conditions for Sazanno and hybridization. Conditions for hybridizing with a corresponding salt may be mentioned.
- the DNA of the present invention may encode all of the constant region and the variable region of the heavy chain and ⁇ , but may also encode only the si member and the variable region of the vehicle.
- the nucleotide sequence of the constant region of translation and vehicle translation when all of the constant region and variable region are encoded is described in Nucleic Acid Research Vol. 14, pl779, 1986, The Journal of Biological Chemistry v. 1.257, pl516, 1982 and Cell vol.22, pl97, 1980 are preferred.
- Examples of the DNA of the present invention encoding the constant region and the variable region include a DNA having a base sequence of Rooster sequence number 129 (heavy chain) and Rooster example number 131 mi).
- the DNA of the present invention can be obtained, for example, by the following method.
- total RNA is prepared from a cell such as the hybridoma of the present invention using a commercially available RNA extraction kit, and cDNA is synthesized by a reverse transcriptase using a random primer or the like.
- the cDNA encoding the antibody is amplified by PCR using the oligonucleotides of the conserved sequences in the variable regions of the known human antibody heavy chain gene and the black fiber gene, respectively, as a primer.
- the sequence encoding the constant region can be obtained by amplifying a known sequence by the PCR method.
- the nucleotide sequence of DNA can be determined by a conventional method, for example, by incorporating it into a plasmid for sequencing.
- the present invention also provides a transformant containing the DNA of the present invention, and a transformant comprising the ffli santan vector.
- Eto Itoh is a vector like Echerichia coli.
- a vector that can be expressed in a nuclear cell for example, pBR322, PUC119 or a derivative thereof
- a vector that can be expressed in a fiber cell is preferable, and a vector that can be expressed in a cell derived from a mammal is more preferable.
- Examples of vectors that can be expressed in mammalian cells include plasmid vectors such as pcDNA3.1 (Invitrogen II) and virus vectors such as DON-AI DNA (Treasure Bioshelf).
- the transformant into which the recombinant vector of the invention is introduced may be a prokaryotic cell such as a fungus, but is preferably a difficult cell, more preferably a cell derived from a mammal.
- Examples of the cells include Chinese hams evening ovary cells (CH0 cells) and the like.
- the hybridoma of the present invention is a hybridoma that produces a monoclonal antibody as described above.
- Examples of the hybridoma of the present invention include the hybridoma HoAKs-1 strain and the 2F6-1-3F9-1 strain shown in the actual S examples described below.
- the hybridoma of the present invention can be obtained by the following method. First, according to the method of A. Imam et al. (Cancer Research vol. 45, 263 1985), cancer 'infiltrating lymphocytes were isolated from cancer tissue removed from a lung cancer patient, and the cells containing lymphocytes were polyethylene glycol. A hybridoma is obtained by fusing with a mouse.
- the hybridoma of the present invention is prepared by using a protein of about 55 kDa derived from the human spleen cancer cell line PAN C-1 shown in FIG. It can also be obtained by immunizing a mouse and fusing the obtained lymphocytes with mouse myeoma cells.
- the pharmaceutical thread of the present invention comprises the monoclonal antibody of the present invention together with a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carriers include soluble carriers, such as known physiologically acceptable buffers (eg, phosphate buffers), Is a dog-like carrier such as latex beads.
- the pharmaceutical composition of the present invention is suitably used as a therapeutic agent for cancer, particularly for non-small cell cancer, knee cancer or gastric cancer.
- the pharmaceutical fiber of the present invention may utilize the effect of the monoclonal antibody itself on the wound damage or growth inhibition, or may bind the monoclonal antibody of the present invention to an iJ3 ⁇ 4g agent such as adriamycin. May be used to target an anticancer drug to a cancer tissue.
- a particularly advantageous pharmaceutical fiber is one obtained by binding the antibody of the present invention to a liposome containing a toxin or an iJ3 ⁇ 4S agent.
- the ribosome carrying the antibody is composed of a double lipid layer, but any one having a multi-layered preparation layer or a single layer can be used.
- Phosphatidylcholine, cholesterol, phosphatidylethanolamine, and phosphatidine as a charge-imparting substance are used as the components of the liposome.
- cholesterol is 0.3 to 1 mol, preferably 0.4 to 0.6 mol
- phosphatidylethanolamine is 0.1 to 0.1 mol per mol of phosphatidylcholine.
- the composition ratio of 0.2 mo 1 is preferably 0.02-0. Lmo 1, and that of phosphatidic acid is 0 to 0.4 mo 1, preferably 0 to 0.15 mo 1.
- a known method can be used for the production method of ribosome. For example, after removing the solvent, the mixture is emulsified with a homogenizer or the like, and after condensing and melting, multilamellar ribosomes are obtained. In order to further adjust the particle size, supersonic, high-speed homogenization, or uniform pores are used. It can be produced by using a pressure filtration method (Biochimica et Biophysica Acta vol. 81, p55, 1985) with a membrane having The size of the ribosome is preferably from 30 nm to 20 O nm.
- Drugs to be encapsulated in the ribosome include anti-cancer drugs such as adriamycin, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, methotrexet, 5Fu (5-fluorouracil), aclacynomycin, ricin A, diphtheria toxin, etc. Toxins, antisense RNA and the like can be used.
- the drug can be encapsulated in the ribosome by hydrating the S substance with an aqueous drug solution. Adriamycin, daunomycin, and epirubicin can also be encapsulated using the H-gradient remote loading method (Cancer Res. Vol. 49, p5922, 1989).
- Methods for binding the monoclonal antibody on the ribosome surface include a method in which a purified antibody is introduced into the liposome by attaching a 7k substance, and a method in which phosphatidylethanolamine and the antibody are cross-linked with glutar.
- a liposome containing a maleimide group-introduced lipid is prepared, the S agent or toxin is encapsulated, and the two are reacted to bind the antibody to the liposome surface.
- a water-soluble polymer derivative having a reaction site with an amino group and a thiol group or a potential thiol group can also be suitably used (Japanese Patent Application Laid-Open No. 11-152234).
- a thiol group to an antibody can be performed by adding N-succinimidyl-1- (2-pyridyldithio) propionate (SPDP), which is commonly used for thiolation of proteins, to iminothiolane, mercaptoalkylimidate, etc.
- SPDP N-succinimidyl-1- (2-pyridyldithio) propionate
- a method of using a compound or a method of reducing an endogenous dithiol group of an antibody to a thiol group may be used, and a method of using an endogenous thiol group is more preferable from the viewpoint of activity.
- Antibodies are converted into F (ab,) 2 by an enzyme such as pepsin, reduced with dithiothreitol (DTT) ', etc., and converted into F (ab,) 2 to form one to three new thiol groups. Can also be subjected to a binding reaction with liposomes. Maleimide group-containing ribosomes can be conjugated with thiolated antibodies by reacting them for 2 to 16 hours in a neutral buffer (pH 6.5-7.5).
- the preparation of the cancer therapeutic agent of the present invention can be carried out by a known method, that is, a lunar method (Japanese Patent Application Laid-Open No. 2-502348), a method of adding a stabilizer and using it as a liquid (Japanese Patent Application Laid-Open — No. 9331) and a freeze-drying method (JP-A-64-9331).
- This onset Ming cancer therapeutic, and intravascular administration, intraperitoneal, etc. can be force s used topical administration, the projecting Azukaryou is by agents contained in the ribosome, respectively to the optimum amount of Can be.
- the dose can be used as an adriamycin amount of 5 O mg / kg or less, preferably 1 O mg / kg or less, more preferably 5 mg / kg or less.
- the diagnostic of the present invention includes a diagnostic reagent utilizing the cancer cell specificity of the antibody of the present invention. More specifically, a diagnostic reagent for cancer comprising the secondary antibody of the antibody of the present invention, a detection substrate, and the like. And the like.
- the polypeptide of the present invention specifically binds to a protein of about 55 kDa (a protein containing the amino acid sequence of Rooster No. 107) derived from human spleen carcinoma cell line * PANC-1 shown in FIG.
- the polypeptide to be recognized It is a polypeptide that does not cause morphological change in normal cells and causes morphological change in cancer cells.
- the morphological change includes, for example, a morphological change of normal cells to an axon-shaped morphology as shown in FIGS. .
- polypeptide of the present invention specifically, a polypeptide which can be adsorbed on process A shown in Examples described later can be mentioned. More preferably, the monoclonal antibody of the present invention is used.
- the polypeptide of the present invention induces morphological changes specifically in cancer cells, so that it can be used as a therapeutic agent for pharmaceuticals, especially for the treatment of cancers such as non-small cell reversion cancer, B-extracted cancer, and gastric cancer. Can be used. ⁇ row
- a cancer tissue removed from a lung cancer patient is made into a small mass with a scalpel, and a culture solution A (RPM I 164 0 + 50 After shaking well in zg / ml gentamicin sulfate, the culture night (I) was recovered. In addition, small pieces of cancer plaiting were finely loosened with a force razor blade, and pitting was performed in a new culture solution to disperse the cells. This cell suspension was centrifuged at 1000 rpm for 5 minutes to recover the supernatant (II). I and II were combined and centrifuged at 3000 rpm for 5 minutes to finally obtain about 4 ⁇ 10 7 cells containing cancer-infiltrating lymphocytes.
- Cells containing cancer-infiltrating linnospheres were fused with mouse myeloma cells (approximately 4 ⁇ 10 7 ) using polyethylene glycol 1500 (Roche Diagnostics) according to a conventional method (Cancer Research vol. 45, 263, 1985). .
- the fused cells were suspended in culture solution B ( ⁇ ⁇ nutrient solution A + 10% ⁇ month-old baby serum (FCS)) to a cell density of 5 ⁇ 10 5 / ml.
- the seeds were seeded in 100 ⁇ 1 aliquots on a 96 ⁇ er plate, and the culture was started in 37 (( 2 incubates) overnight.
- the above cancer broth is cultured in a 96-well plate for 3 to 4 days until further growth. Then, the supernatant was removed, and after one round of competition with 1 OmM phosphate buffer (pH 7.4, 0.15 M NaCl) (PBS), the cells were fixed with 2% paraformaldehyde (room temperature, 20 minutes). After 5 times with PBS, 5% BSA (pserum albumin) -containing PBS scythes were added at 150/1 / well to perform blocking. The plate was competed five times with PBS, and 50 ⁇ 1 hybridoma culture supernatant was added and reacted at 37 ° C. for 1.5 hours.
- 1 OmM phosphate buffer pH 7.4, 0.15 M NaCl
- the cells were competed five times in P83, and a goat antibody (diluted in 1,000-fold, Capel) against a human antibody bound to 501 horseradish peryloxidase (HRP) was added. A time reaction was performed. Then, the plate with PBS containing 0.05% 0. The Tween20 (PBS-T) and 3 ⁇ 43 ⁇ 4 War, o- phenylene Renjiamin 3 ⁇ 4 Hokusatsu (5. 2%) and H 2 0 2 (0. 0 15 %) was added at a rate of 50 1 / well, and the mixture was allowed to react at room temperature until color development was confirmed. The absorbance at 490 nm was measured by a microphotometer (Nippon Intermed).
- HoAKs-1 antibody the monoclonal antibody obtained from this strain.
- the fetal serum was passed through a protein A-glass bead column (Procept A) (bio PROCESSING) and processed. Serum from which the substance adsorbed on A was removed was prepared, and the hybridoma HoAKs-11 was cultured using the culture solution A containing 7 to 10% of this serum.
- the culture solution obtained by culturing the hybridoma HoAKs-1 was applied to Prosep A to adsorb the polypeptide A-adsorbed polypeptide, and then eluted to purify the polypeptide adsorbed to Prosep A. This polypeptide having the Procept AP attached thereto was subsequently used as the HoAKs-1 antibody.
- the HoAKs-1 antibody purified by Procept A was labeled with biotin using Biotinylation Reagent (Amersham Pharmacia Biotech) according to the manufacturer's instructions, and the gel and the free biotin were separated by gel filtration. separated.
- Lung cancer cell line HLC-1, gastric cancer cell line 45, ⁇ cancer cell line PANC-1 (NCTCC No. CRL 1469) were used as human cancer cells, and vascular endothelial cell HUVECs (Dainippon Pharmaceutical) were used as normal human cells. Tengchong these cancers information, maintenance, and grown at 37 ° C, of 5% C0 2 conditions in culture D. Human vascular endothelial cells, HUVECs, were grown using the culture medium CS-C culture medium (Cell systems).
- the HoAKs-1 antibody is sterilized by filtration through a filter overnight, diluted with culture medium C or CS-C culture medium to a fiber of about 140 ⁇ g / m 1, and added to a 96-well plate. 1 / 'dispensed in aliquots.
- each of the cultured cancer cells and vascular endothelial cell HUVECs was diluted to a density of 3 ⁇ 10 4 / ml with culture medium C containing 10% human serum (ICN Biomedicals) or CSC-culture medium, respectively.
- the cell-containing solution was seeded at 100 1 / well, so that the number of cells in the well was 1.5 ⁇ 10 3 / well, and the concentration of the HoAKs-1 antibody was adjusted to about 70 g / ml.
- the HizaganHoso Zhu PAN C-1 recognized morphologies Heni spoon, cell number LXL 0 3 / Ueru become as 96 Ueru first plate tides' weigh in Ueru, HoAKs - 1 concentration of the antibody 30 0 zg / ml N 100 ⁇ G / ml, the I ⁇ become conditions 30 ⁇ G / ml, and cultured at 37 ° C, 5% C0 2 environment, 3 times every other day, the culture supernatant Were replaced under the same conditions as above, and the number of live cancer cells was compared on the 6th day using a prodoxyduridine (BrdU) cell proliferation assay kit (manufactured by Oncogene). . According to the sixth statement, Brd U solution was added to each well according to the kit's instructions, cultured overnight, and the amount of BrdU incorporated into live cancer cells was measured on the 7th day . For comparison, similar experiments were performed using human antibody IgM.
- various types of cancer such as lung cancer (Lung Cancer Shoe Ver .: HLC-1 (Keio University), A549 and PC-9 (Immune Biology Research Institute, Knee Cancer Subdivision: SUIT 2 (Kyushu Cancer Center), PANC-1) And PK8 (Medical Cell Resources Center, Institute of Aging Medicine, Tohoku University), Gastric cancer: MKN45, MKN74, HSC-3 (all immunobiological research), Cancer: HT29 (ATCC No.
- DLD -1 ATCC No. CCL221)
- LoVo ATCC No. CCL229
- CO L0205 ATCC No. CCL 222
- Approximately 1 ⁇ 10 6 to 1 ⁇ 10 7 cells were implanted subcutaneously into nude mice (CLEA Japan) to form tumors, and the formed tumors were excised and treated as described above. ⁇ Tissue sections were prepared.
- the prepared various pieces were deparaffinized according to a conventional method, subjected to a blocking operation, and reacted with the biotin-labeled Ho AKs-1 antibody described in Difficult Example (3) -2.
- the detection was performed using DAKO Catalyzed Signal Amplifier (CSA) System (DAKO), and the reactivity was detected as reddish brown staining of diaminobenzidine. Further, in the tissue section subjected to the immunostaining, the nuclei of cells in the tissue were stained blue with hematoxylin in order to confirm the histological image.
- CSA DAKO Catalyzed Signal Amplifier
- FIG. 4 shows stained images of various cancer tissue sections and autologous lung non-cancerous tissue sections in which reactivity was observed.
- HoAKs-1 antibody is used to identify the cancer in the autologous lung cancer tissue from which the hybridoma was derived and the lung cancer tumors formed in nude mice: HLC-1 and A549; 1 and PK-8, gastric cancer tumor: MKN45 tumor Tumor tumor cells showed clear reactivity. On the other hand, non-cancer group was not found.
- a human antibody purified from human serum using a Prosep A column in the same manner as the HoAKs-1 antibody, or an antibody having the same subtype as the HoAKs-1 antibody obtained in the same manner as the HoAKs-1 antibody Staining using gM human monoclonal antibody A was also performed in the same procedure as described above. These antibodies did not have the potential for the insoluble fraction of PANC-1 cells, but did not show any specific reactivity with the above tissue sections.
- ⁇ -buffer (1 OmM Tris-HCL (pH 7.6), 15 OrnM NaCl, ImM EDTA) + protease inhibitor (5/1 g / m 5 ll gm 1vpstatin A and 10 g (v / v) of the cells from which 5 gm 1 chymosintin (both from Peptide Laboratories) were collected, and using a glass homogenizer under ice-cooling. The cells were disrupted by centrifugation and centrifuged at 10,000 g for 20 minutes to obtain a soluble supernatant fraction and an insoluble supernatant.
- RIPA-buffer (5 OmM Tris-HCL (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1%
- FIG. 5 shows the electrokinetic pattern of the protein derived from P ANC-1 cells (Coomassie Briant Blue stain) and the results of Western blotting.
- the HoAK s-1 antibody was found to exhibit a] 3 ⁇ 45 property to a single protein of about 55 kDa in the insoluble fraction (membrane fraction) of the homogenate of pan PAN C-1 cell homogenate.
- the Si3 ⁇ 4 substance of Ho AKs-1 was detected on the two-dimensional electrophoresis pattern.
- the same sample was subjected to two-dimensional electrophoresis 13 times, and the gel after electrophoresis was stained with C 00massie Brilliant Blue. Based on the results of the Western blot, the gel was compared with the HoAKs-1 antibody reactant. The corresponding spot was cut out from the gel for 13 pieces.
- the HoAKs-1 antibody is thought to have exerted a morphological change (Fig. 1) and a growth inhibitory effect (Fig. 2 or 3) on cancer cells via a protein containing this amino acid sequence VELQELNDRFAN (Rooster S ⁇ J No. 107).
- Fig. 1 a morphological change
- Fig. 2 or 3 a growth inhibitory effect
- this protein was found to be present on the cancer cell membrane surface. As expected.
- RNA PGR KIT AMV
- TaKaRa RNA PGR KIT
- PCR primers VH1 (SEQ ID NO: 1), VH2 (SEQ ID NO: 3), and VH3 (SEQ ID NO: 1) corresponding to the N-terminal amino acid sequence (SEQ ID NO: 2, 4, 6, 8, 10, and 12) conserved in step 1 No.
- VH4 SEQ ID NO: 7
- VH5 SEQ ID NO: 9
- VH6 SEQ ID NO: 11
- PCR primers corresponding to the C-terminal amino acid sequence SEQ ID NOs: 14, 16, 18, and 20
- JH1 SEQ ID NO: 13
- JH2 SEQ ID NO: 15
- JH3 SEQ ID NO: 17
- JH4 SEQ ID NO: The same mixture of 19 was used on the third side.
- the primer for amplifying the chain variable region is stored in frame 1 of the human antibody chain variable region.
- N-terminal amino acid sequences SEQ ID NOS: 22, 24, 26, 28, 30, and 32
- VK1 Roomster J No. 21
- VK2 Roomster Column No. 23
- VK3 Legend number 25
- VK4 SEQ ID NO: 27
- VK5 SEQ ID NO: 29
- VK6 SEQ ID NO: 31
- PCR primers JK1 (SEQ ID NO: 33), JK2 (SEQ ID NO: 35), JK3 (SEQ ID NO: 37), and PCR primers corresponding to the C-terminal amino acid sequences (SEQ ID NOs: 34, 36, 38, 40, and 42), respectively.
- the N-terminal amino acid sequence (SEQ ID NOs: 44, 46, 48, 50, 52, 54, and 56) conserved in frame 1 of the human antibody variable chain variable region was The corresponding PCR primers VL1 (SEQ ID NO: 43), VL2 (Rooster B ⁇ No. 45), VL3 (Rooster [J No. 47), VL4 (SEQ ID NO: 49), VL5 (SEQ ID NO: 51) ⁇ VL6 (SEQ ID NO: 53), an equal mixture of VL7 (SEQ ID NO: 55) at the 5 'end, a human antibody; and a C-terminal amino acid sequence (Rod example numbers 58, 60 and 62) conserved in frame 4 of the I chain variable region.
- Equivalent mixtures of the corresponding PCR primers JL1 (SEQ ID NO: 57), JL2 (SEQ ID NO: 59), and JL3 (SEQ ID NO: 61) were used at the 3 ends.
- the PCR reaction was performed using Perk in Elmer Gene Amp PCR System 2400 and RNA PCR KIT (AMV) (TaKaRa) according to the instruction manual.
- AMV RNA PCR KIT
- TaKaRa RNA PCR KIT
- the amplified variable region DNA fragments of each of the heavy and light chains were purified using MinElute PCR Purification Kit (QIAGEN). Next, TOPO
- pCR2.1-TOP0 pCR2.1-TOP0 and the above purified PCR product were linked to each other to transform Escherichia coli. Pick up the resulting colonies, purify the plasmid using QIAGEN Plasmid mini kit (QIAGEN), digest with EcoRI at 37 ° C for 15 minutes, and incorporate the desired DNA fragment by 2% agarose electrophoresis. It was confirmed.
- the nucleotide sequence was determined for multiple colonies in which the DNA fragment of interest was integrated. Using the imaz, the corn was ligated using the CEQ 2000 DNA Analysis System (Beckman). As a result, four types of sequences, H09 (SEQ ID NO: 63), H12 (Rooster B ⁇ No. 65), H27 (SEQ ID NO: 67), and H30 (Rooster ⁇ ) No. 69, were obtained from the heavy chain cage. . From the cage of the K chain, K30 (SEQ ID NO: 71), K31 (Rooster No.
- K32 SEQ ID NO: 75
- K35 Legend number 77
- K39 SEQ ID NO: 79
- KM05 SEQ ID NO: 97
- KM06 Rooster H ⁇ No. 99
- KM026 SEQ ID NO: 101
- KM036 SEQ ID NO: 103
- KMO 40 SEQ ID NO: 105
- H09, HI2, H27, H30, K30, # 31, # 32, # 35, and # 39 were considered to encode human heavy chains or fractions.
- the rooster H ⁇ in the region 3 'further from the sequence described above was determined.
- the amplification of the 3 side region of the heavy fiber gene was carried out by using the PCR framer VH3 (SEQ ID NO: 5) corresponding to the N-terminal amino acid rooster conserved in frame 1 of the heavy chain variable region of the human antibody.
- PCR was performed using PCR primer IgMFOR (SEQ ID NO: 108) corresponding to the amino acid rooster in the normal region of the human antibody, and using the three-sided primer.
- the obtained PCR product was inserted into a plasmid in the same manner as described above, and the nucleotide sequence was determined.
- a 57-base sequence (Rooster Example No. 110) following the third side of the base sequence of the heavy chain variable region (SEQ ID No. 81) could be newly obtained.
- This nucleotide sequence was predicted to encode 19 amino acids (number 111).
- the nucleotide sequence of the HoAKs-1 antibody heavy chain 1 gene to which the 57 bases were added and the predicted amino acid sequence are shown in SEQ ID NO: 118 and SEQ ID NO: 119, respectively.
- this 57 base since sequences are included to co one de constant region, portions encoding the variable region (24 bases) only H 0 eight 1 ⁇ -1 antibody MigakuSada variable territory ⁇ plus The nucleotide sequence of the advisor and the predicted amino acid sequence are shown in SEQ ID NO: 114 and SEQ ID NO: 115, respectively.
- Amplification of HoAKs-1 antibody fiber gene was performed using the PCR primer VK4 (SEQ ID NO: 27) corresponding to the N-terminal amino acid sequence stored in frame 1 of the human antibody / c chain variable region.
- PCR was performed using a PCR primer GKFOR (SEQ ID NO: 109) corresponding to the C-terminal amino acid sequence of the human antibody arm normal region as the 5′-side primer, using the PCR primers used for the three-side primer.
- the obtained PCR product was inserted into a plasmid in the same manner as described above, and the nucleotide sequence was determined.
- the base sequence of the above-mentioned chain variable region (SEQ ID NO: 83), the sequence of 99 bases following the 3 ′ side (Rooster [
- This nucleotide sequence was predicted to encode 33 amino acids (SEQ ID NO: 113).
- the nucleotide sequence of the ⁇ Ks-1 antibody chain gene to which the 99 bases were added and the predicted amino acid H ⁇ J are shown in No. 120 and No. 121, respectively.
- these 99 bases include the motif of the constant region, the HoAKs-1 antibody has only the variable region-encoding portion (24 bases).
- ⁇ base sequence of the chain variable region gene
- the predicted amino acid sequence are shown in SEQ ID NO: 116 and Rooster!], Respectively.
- CDR hypervariable region
- the framework was determined by Kabat et al. (Sequences of Proteins of Immunological Interest, fifth edition National Institutes of Health, Bethesda, MD 1991).
- CDRs of the heavy chain were HCDR 1 (base sequence: SEQ ID NO: 85, amino acid sequence: ⁇ number 86), HCDR2 (base II:.: Rooster 1) number 87, and amino acid sequence: rooster H ⁇ y number 88 )
- H CDR3 base sequence: SEQ ID NO: 89, amino acid sequence: 0
- car 11 Sada CDRs are LCDR1 (base sequence: SEQ ID NO: 91, amino acid sequence: SEQ ID NO: 92), LCDR2 (base sequence: SEQ ID NO: 93, amino acid sequence: SEQ ID NO: 94) and LCDR 3 (base sequence: It can be identified as Rooster sequence number 95, amino acid sequence: SEQ ID NO: 96).
- FIG. 7 shows the binding activity of the Ho AKs-1 antibody to the surface of each living cell.
- HoAKs-1 antibody showed binding activity to the live cell surface of PANC-1 cells and HLC-1 cells (Fig. 7—A, C), but did not show binding activity to HUVECs cells (Fig. 7).
- -E The human gM antibody used as a control did not show any binding activity to any of the cells (FIG. 7—B, D, F).
- Tsuru Example (6) Prepare an insoluble fraction protein solubilized with RIPA buffer from a homogenate of PANC-1 cells in the same manner as in (1) -1, and use a 10% acrylamide gel for about 180 ⁇ g. Electrophoresis was performed. The gel and the gel were stained with Coomassie Brilliant Blue, and a band corresponding to about 55 kDa protein, to which the HoAKs-1 antibody was reactive, was cut out.
- the excised gel was crushed, mixed with 0.2 ml complete Freund's adjuvant (manufactured by DI FCO LABORATORIES), and injected into the abdominal cavity of a mouse (Balb / c AJc1, 6-week-old, CLEA Japan), A first immunization was performed. Two weeks later, the incomplete adjuvant and the gel were mixed, prepared in the same manner as described above, and the mice were immunized again. Four days later, the spleen of the mouse was removed and lymphocytes were prepared (2.4 10 8 Then, the cells were fused with mouse myeloma cells P3U1 according to a standard method (Monoclonal Antibody Experiment Manual, published by Kodansha Scientific Ltd.).
- the fused cells were suspended in culture medium D (eRDF + 50 g / m1 genmycin «+ 10% FCS) plus normal HAT, and seeded on a 96-well plate. ° culture was started in C0 2 incubator beta scratch. Approximately 2 weeks after fusion, the appearance of hybridomas was confirmed, and using the culture supernatant, the reactivity to the approximately 55 kDa protein was detected by Western blotting, and the desired hybridoma was selected. .
- culture medium D eRDF + 50 g / m1 genmycin «+ 10% FCS
- FCS normal HAT
- Insoluble fraction protein solubilized in a RIP A buffer from a homogenate of PANC-1 cells Approximately 4 mg of the protein was electrophoresed on a 10% acrylamide gel, and the protein was transferred from the gel to a PVDF membrane. And blocked. (10) The culture supernatant of each 96-well plate was collected and reacted with the transferred PVDF membrane at 37 ° C for 1 hour. The VDF membrane was washed with PBS-II, a goat antibody (1000-fold dilution, Capel) against the mouse antibody bound to HRP was added, and the reaction was further performed at 37 ° C for 1 hour.
- the PVDF membrane was washed with PBS-T, and the activity of the culture supernatant to about 55 kDa evening protein was detected using Konikai Munostin HRP-1000 (manufactured by Konikaki Co., Ltd.). Cloning was performed by limiting dilution from the wells in which iS property was detected, and hybridoma strains 2F6-1 and 3F9-1 were established.
- the hybridoma strains 2F6-1 and 3F9-1 established in (10) -2 were cultured, and the respective culture supernatants were collected and applied to Prosep A to purify the antibody. SDS-PAGE confirmed that each of the monoclonal antibodies was IgM. After purifying each antibody using Biotin Reagent according to the instruction manual, the labeled antibody and free biotin were separated by gel filtration.
- 'PANC-1 Insoluble fraction protein solubilized with R-PA buffer from the homogenate of Itoda Tsukiha, about 10 g per lane of 10% acrylamide gel, electrophoresed, and the protein was transferred from gel to PVDF membrane. Transfer was performed for blocking.
- Anti-vimentin mouse monoclonal antibody (sc-6260, Santa Cruz Biotechno 1 og-i) and goat anti-desmin antibody (sc-7559 ⁇ Santa Cruz Biotechno 1 ogy shelf with PVDF membrane and 37.C, 1 hour After the reaction, the PVDF membrane was washed with PBS-T, and a goat antibody (1000-fold dilution, Capel) against the mouse antibody bound to HRP or a mouse antibody (1000-fold dilution) against the goat antibody was added. The reaction was performed for 1 hour at 0 ° C.
- the PVDF membrane was washed, and the reactant of the antibody was detected with a well-tanning luminol reagent.
- the anti-vimentin antibody was approximately 55 kDa. Showed anti-desmin antibody S ⁇ property but not detected
- HoAKs-1 antibody recognizes approximately 55 kDa
- the protein was determined to be vimentin, and it was proved that some antibodies reactive with the protein had binding activity to the surface of live cancer cells.
- variable regions of the fil and / or ⁇ chains For amplification of the variable regions of the fil and / or ⁇ chains, a primer into which a restriction enzyme site for ligation with an expression plasmid was introduced was used.
- P2 SEQ ID NO: 123) containing a Hind III site and a signal sequence on the 5 'end side, and P3 containing a NheI: site on the end shelf (Torumi column number 124)
- P4 SEQ ID NO: 125
- P5 SEQ ID NO: 126) containing a Bs iWI site at the 3' end were used. .
- the amplified variable region DNA fragments of the heavy chain and K chain were purified using QI Quick PCR Purification Kit (QIAGEN).
- the DNA fragment was digested with a restriction enzyme to ligate it to the expression vector.
- the heavy chain DNA fragment was digested with Hindi II and Nhe I at 37 ° C for 2 hours.
- the strand DNA fragment was first digested with BsiWI at 37 ° C for 2 hours, purified with QIAquick PCR Purification Kit (QIAGEN), and further digested with HindIII at 37 ° C for 2 hours.
- the resulting DNA fragment was subjected to 1.5% agarose gel electrophoresis, and the desired DNA fragment was purified using QI Ack gel Extraction Kit (Q I AGEN).
- pKS— £ — Hind— 5 was digested with Asp718 at 37 ° C for 2 hours, purified with QIAquick PC Purification Kit (QI AGEN), and further digested with Hind111 at 37 ° C for 2 hours. . The digested fragment was subjected to 0.8% agarose electrophoresis, and the target fragment was purified using a QIAquick Gel Extraction Kit (QIAGEN).
- the DNA fragment containing the Constitutive variable region of HoAKs-1 obtained by the above method and the digested expression plasmid pEX-G1-WLpHy were obtained using the Ligation Kit Ver. 2.1 (TAKARA).
- the cells were ligated according to the manufacturer's instructions, and transformed with Escherichia coli DH5-hiT1 (Invitroen) according to the manufacturer's instructions.
- the resulting colony was picked up and the plasmid was purified using QIAprep Spin Miniprep Kit (QIAGEN).
- the plasmid containing the nucleotide sequence was digested with Ndel at 37 ° C for 1 hour, and subjected to 1.5% agarose electrophoresis to obtain a desired plasmid pEX-HoAKs-H.
- SEQ ID NO: 1228 was used to confirm the nucleotide sequence.
- SEQ ID NO: 129 shows the nucleotide sequence of the heavy chain structural gene of the HoAKs-1 recombinant antibody.
- the expression plasmid pKS- / C'-Hind-5 digested with the DNA fragment containing the chain variable region of HoAKs-1 was prepared using the Liation Kit Ver. 2.1 (TAKA A), And transformed into ⁇ ISDH5a-Tl (Invitrogen). The resulting colonies were picked up and the plasmid was purified using QI Aprep Spin Miniprep Kit (QIAGEN). The plasmid containing the chain base sequence was digested with BsiWI at 37 ° C for 1 hour, and subjected to 1.5% agarose electrophoresis to obtain a desired plasmid pKS-HoAKs-K.
- the plasmid obtained above was digested with restriction enzymes to ligate the heavy chain and the chain of HoAKs-1 into one plasmid.
- pEX-11013-11 was digested at 37 ° C for 2 hours at 1161 and 1: 3-110-813-1-1 was digested at 37 ° C for 37 hours at 37 ° C for 2 hours.
- the fragments were purified using the QIAquick PC Purification Kit (QIAGEN), and each fragment was ligated using the Ligation Kit Ver. 2.1 (TAKARA) according to the manufacturer's instructions.
- the resulting colonies were picked up, and the plasmid was purified using QIAprep Spin Miniprep Kit (QIAGEN) The resulting plasmid was digested with NheI at 37 ° for 30 minutes. Then, 0.8% agarose electrophoresis was performed to obtain a desired plasmid pEX-HoAKs-HK.
- Plasmid p: SV: 2dhf r "containing the pEX-110 1 ⁇ -111: and (] 1: 0 ⁇ > genes obtained above was linked to r-HoA.
- pEX-HoAKs-HK was digested with BamHI and NheI at 37.C for 2 hours, then electrophoresed with 0.8% agarose, and the target DNA fragment was subjected to QIAquick Gel.
- Each fragment was ligated using Ligation Kit Ver. 2.1 (TAKARA) according to the instructions, and Escherichia coli DH5HiTl (Invitrogen) was transformed. The resulting colonies were picked up and the plasmid was purified using QI Aprep S in Miniprep Kit (QI AGEN). The resulting plasmid is After digestion at 37 ° C for 1 hour at 61 ° C, the desired plasmid pEX—HoAKs—HK / pSV2dhfr ′ for expressing 1.5 ⁇ g Agarose-based antibody and expressing the Antan ⁇ antibody
- CH ⁇ (DG325) cell J3 which can be cultured in a serum-free medium, was used.
- CHO (DG325) was adjusted to 1 ⁇ 10 6 ce 11 s / ml with CHO—S—SFMI I (GIBC0).
- 2 g of pEX—HoAKs_HK / pSV2dhfr ', DNA and 6 / L of FuGENE 6 (Roche) were mixed and transfected to CHO (DG325) according to the instructions.
- EX-CELL325-PF (Nichirei) was added.
- Culture for 2 days G418 Sulfate (Promega) 40 O ⁇ zg / ml and methotrexate (Sigma) 0, 25, or 50 nM were added to the medium, and cultured. Cells were produced.
- the amount of AA-HoA. Produced by the cells was measured by the sandwich ELISA method. First, dilute a heron anti-human immunoglobulin antibody (CAPPEL) to 50 / g / ml with solution 1 (PBS). Each 50 L we 11 was added to a flexible plate (FALCON) and treated at 37 ° C for 2 hours. Thereafter, the solution of we11 was discarded, and 200 L of solution 2 was added to each well, followed by treatment at 4 ° C for 16 hours or more. Discard each we11 solution, add 5 Oju L / well of culture supernatant diluted with solution 2 (0.1% Gelat in / PBS / 0.05% Tween20), and react at 4 ° C for 16 hours or more.
- CAPPEL heron anti-human immunoglobulin antibody
- the A-Ho A. production details obtained above were cultured in EX-CELL 325-PF (Nichirei) supplemented with G418 Sulfate (Promega) and methotrexate (Sigma), and r-HoA. Was obtained.
- r-HoA. was adsorbed by applying the culture solution to Procept A, and then eluted to purify e-HoA.
- r-HoA. was confirmed to be pure IG by SDS-PAGE.
- the insoluble fraction protein solubilized in the RI PA buffer from the homogenate of PANC-1 cells was subjected to electrophoresis for 10 g of each protein using a 10% acrylamide gel, and the protein was transferred from the gel to a PV-DF membrane. Blocked.
- the transferred PVDF membrane was incubated with the purified HoA. Described in (13-7) for 1 hour at 37 ° C.
- the PVDF membrane was washed with PBS-T, a goat antibody (1000-fold dilution, Capel) against a human antibody bound to HRP was added, and the reaction was further performed at 37 ° C for 1 hour. Next, the PVDF membrane was washed with PBS-T, and the reactivity of ⁇ -HoA.
- HizaganHoso Zhu P ANC-Ted Stevens 1 seeded with lung cancer cell lines HL C-1 and vascular endothelial cells HUVE C s 96- ⁇ El plates (3603, co one Ningune Qian), the cultured at 37 5% C0 2 environment After one day, the refiner described in (13-7) (containing 0.05% sodium azide) was added, and the mixture was reacted at room temperature for 60 minutes. After removing the solution, react with a goat antibody (20-fold sickle, Capel) (containing 0.05% sodium azide) against FITC-conjugated human antibody for 30 minutes at room temperature.
- FIG. 9 shows the binding activity of the antibody to the surface of each living cell.
- HoA. Like HoAKs-1 described in (9), showed binding activity to PANC-1 Itoda vesicle and HLC-11 cells on the live cell surface (Fig. 9A, C). ) Did not show binding activity to HUVEC s cells (Fig. 9-E).
- a cancer therapeutic agent that remotely attacks cancer tissue particularly non-small cell lung cancer, knee cancer or gastric cancer
- cancer tissue particularly non-small cell lung cancer, knee cancer or gastric cancer
- the human monoclonal antibody of the present invention it is possible to provide a therapeutic agent for cancer that can be continuously administered with few side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04715540A EP1598419A1 (en) | 2003-02-28 | 2004-02-27 | Monoclonal antibody, gene encoding the same, hybridoma, medicinal composition and diagnostic reagent |
US10/546,594 US7396915B2 (en) | 2003-02-28 | 2004-02-27 | Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent |
CA002515389A CA2515389A1 (en) | 2003-02-28 | 2004-02-27 | Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical compostion, and diagnostic reagent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-054670 | 2003-02-28 | ||
JP2003054670 | 2003-02-28 | ||
JP2003-194643 | 2003-07-09 | ||
JP2003194643 | 2003-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004076658A1 true WO2004076658A1 (ja) | 2004-09-10 |
Family
ID=32929675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/002402 WO2004076658A1 (ja) | 2003-02-28 | 2004-02-27 | モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7396915B2 (ja) |
EP (1) | EP1598419A1 (ja) |
KR (1) | KR20050106459A (ja) |
CA (1) | CA2515389A1 (ja) |
WO (1) | WO2004076658A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005089797A2 (de) * | 2004-03-09 | 2005-09-29 | Lts Lohmann Therapie-Systeme Ag | Trägersystem in form von nanopartikeln auf proteinbasis zur zellspezifischen anreicherung von pharmazeutisch aktiven wirtstoffen |
WO2008141274A1 (en) * | 2007-05-11 | 2008-11-20 | Centocor, Inc. | Anti-alpha v immunoliposome composition, methods and uses |
WO2022099126A1 (en) * | 2020-11-09 | 2022-05-12 | Lxz Services Llc | Anti-psma antibodies and methods of use |
CN114685671A (zh) * | 2020-12-30 | 2022-07-01 | 深圳华大生命科学研究院 | 特异性结合Taq DNA聚合酶的单克隆抗体及其应用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7255173B2 (en) * | 2002-11-05 | 2007-08-14 | Weatherford/Lamb, Inc. | Instrumentation for a downhole deployment valve |
US20070122414A1 (en) * | 2005-11-10 | 2007-05-31 | Aurelium Biopharma Inc. | Surface marker-directed cancer therapeutics |
CN101501070B (zh) | 2006-02-08 | 2013-12-25 | 诺福泰克公司 | 抗原性gm-csf肽和针对gm-csf的抗体 |
CN101389756A (zh) * | 2006-02-23 | 2009-03-18 | 田边三菱制药株式会社 | 单克隆抗体、编码该抗体的基因、杂交瘤、药物组合物和诊断试剂 |
WO2008156763A2 (en) * | 2007-06-15 | 2008-12-24 | The Board Of Trustees Of The Leland Stanford Junior University | Human neutralizing monoclonal antibodies to h5n1 influenza a virus |
CN101925612A (zh) * | 2007-11-27 | 2010-12-22 | 维文蒂阿生物技术公司 | 针对癌相关的nfkbib变体的表位的抗体及其用途 |
EP2703485B1 (en) * | 2011-03-30 | 2018-12-26 | National University Corporation University Of Toyama | Method for selecting plasma cells and plasmablasts, and method for producing target antigen-specific antibody |
KR102024016B1 (ko) * | 2011-05-04 | 2019-11-04 | 오메로스 코포레이션 | Masp-2 의존적 보체 활성화를 억제하는 조성물 |
CN105209489B (zh) | 2013-03-05 | 2019-06-14 | 得克萨斯州大学***董事会 | 针对间质和上皮-间质转化的循环肿瘤细胞的特异性检测工具 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998055619A1 (de) * | 1997-06-06 | 1998-12-10 | Asat Ag Applied Science & Technology | Anti-gpiib/iiia rekombinante antikörper |
WO2001055437A2 (en) * | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2002002641A1 (en) * | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
GB2378949A (en) * | 2001-08-16 | 2003-02-26 | Morten Steen Hanefeld Dziegiel | Human antibodies against Plasmodium falciparum MSP-3 antigen |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727021A (en) * | 1984-06-01 | 1988-02-23 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cytokeratin |
-
2004
- 2004-02-27 EP EP04715540A patent/EP1598419A1/en not_active Withdrawn
- 2004-02-27 KR KR1020057015947A patent/KR20050106459A/ko not_active Application Discontinuation
- 2004-02-27 US US10/546,594 patent/US7396915B2/en not_active Expired - Fee Related
- 2004-02-27 WO PCT/JP2004/002402 patent/WO2004076658A1/ja not_active Application Discontinuation
- 2004-02-27 CA CA002515389A patent/CA2515389A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998055619A1 (de) * | 1997-06-06 | 1998-12-10 | Asat Ag Applied Science & Technology | Anti-gpiib/iiia rekombinante antikörper |
WO2001055437A2 (en) * | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2002002641A1 (en) * | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
GB2378949A (en) * | 2001-08-16 | 2003-02-26 | Morten Steen Hanefeld Dziegiel | Human antibodies against Plasmodium falciparum MSP-3 antigen |
Non-Patent Citations (1)
Title |
---|
HUBER C. ET AL: "The Vx genes of the L regions and the repertoire of Vx gene sequences in the human germ line", EUR. J. IMMUNOL., vol. 23, 1993, pages 2868 - 2875, XP002980307 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005089797A2 (de) * | 2004-03-09 | 2005-09-29 | Lts Lohmann Therapie-Systeme Ag | Trägersystem in form von nanopartikeln auf proteinbasis zur zellspezifischen anreicherung von pharmazeutisch aktiven wirtstoffen |
WO2005089797A3 (de) * | 2004-03-09 | 2006-11-23 | Lohmann Therapie Syst Lts | Trägersystem in form von nanopartikeln auf proteinbasis zur zellspezifischen anreicherung von pharmazeutisch aktiven wirtstoffen |
WO2008141274A1 (en) * | 2007-05-11 | 2008-11-20 | Centocor, Inc. | Anti-alpha v immunoliposome composition, methods and uses |
US8138315B2 (en) | 2007-05-11 | 2012-03-20 | Centocor Ortho Biotech Inc. | Anti-alpha V immunoliposome compositions, methods and uses |
WO2022099126A1 (en) * | 2020-11-09 | 2022-05-12 | Lxz Services Llc | Anti-psma antibodies and methods of use |
CN114685671A (zh) * | 2020-12-30 | 2022-07-01 | 深圳华大生命科学研究院 | 特异性结合Taq DNA聚合酶的单克隆抗体及其应用 |
CN114685671B (zh) * | 2020-12-30 | 2023-09-26 | 深圳华大生命科学研究院 | 特异性结合Taq DNA聚合酶的单克隆抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP1598419A1 (en) | 2005-11-23 |
KR20050106459A (ko) | 2005-11-09 |
US7396915B2 (en) | 2008-07-08 |
US20060088538A1 (en) | 2006-04-27 |
CA2515389A1 (en) | 2004-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101683884B1 (ko) | 항-EpCAM 항체 및 이의 용도 | |
JP6728264B2 (ja) | 抗her2抗体及びその結合体 | |
EP3858856A1 (en) | Anti-b7-h3 monoclonal antibody and use thereof in cell therapy | |
US7910100B2 (en) | Antibodies directed to the mammalian EAG1 ion channel protein | |
JP7407841B2 (ja) | クローディン18a2に対する抗体及びその応用 | |
US20030138425A1 (en) | Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof | |
WO2004076658A1 (ja) | モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬 | |
JP2007252372A (ja) | モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬 | |
NZ244661A (en) | Monoclonal antibody against a tumour-associated antigen, the antigen, an epitope, hybridoma, diagnostic aids, vaccines, nucleic acid encoding the antibody (or parts of it) and fusion proteins | |
CN114685670A (zh) | Cldn18.2抗体及其应用 | |
JP2005040126A (ja) | モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬 | |
EP4257612A1 (en) | Development of new tumor engager therapeutic drug and use thereof | |
WO2023001303A1 (zh) | 药物组合物及用途 | |
CN113321730B (zh) | Cldn18.2抗体及其应用 | |
US20090053300A1 (en) | Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent | |
CN116265489A (zh) | 同时靶向人CD73及人TGFβ的双功能融合蛋白、其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004715540 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2515389 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006088538 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10546594 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057015947 Country of ref document: KR Ref document number: 20048052388 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057015947 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004715540 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10546594 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |